Floatz logo

Therapeutic Asset Ratings

3,272 results matching 1 filter

91,565 assets7,904 sponsors3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Mirdametinib
B-Cell Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)P2CC (46)
mk-2206
HER2 Positive Breast Carcinoma
National Cancer Institute (NCI)P2CC (46)
Nilotinib
Ovarian Cancer
National Cancer Institute (NCI)P2CC (46)
Alisertib
B-Cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)P1CC (46)
Azacitidine
Hepatosplenic T-Cell Lymphoma
National Cancer Institute (NCI)P1CC (46)
Cabozantinib
HIV Infectious Disease
National Cancer Institute (NCI)P1CC (46)
C-Car066
B-Cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)P1CC (46)
Cyclophosphamide
Malignant Urinary System Neoplasm
National Cancer Institute (NCI)P1CC (46)
Fludarabine
Small Cell Lung Carcinoma
National Cancer Institute (NCI)P1CC (46)
Ipilimumab
Breast Adenocarcinoma
National Cancer Institute (NCI)P1CC (46)
Romidepsin
Enteropathy-Associated T-Cell Lymphoma
National Cancer Institute (NCI)P1CC (46)
Veliparib
Cancer
National Cancer Institute (NCI)P1CC (46)
Veliparib
Cancer Of Unknown Primary Site
National Cancer Institute (NCI)P1CC (46)
Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap
Prostate Neoplasm
National Cancer Institute (NCI)P1/2CC (46)
Polyethyleneglycol-7-Ethyl-10-Hydroxycamptothecin Dfp-13318
Ependymoma
National Cancer Institute (NCI)P1/2CC (46)
Tolinapant
Fallopian Tube Carcinosarcoma
National Cancer Institute (NCI)P1/2CC (46)
Tolinapant
Ovarian Carcinosarcoma
National Cancer Institute (NCI)P1/2CC (46)
Nogapendekin Alfa Inbakicept
Non-Small Cell Lung Carcinoma
National Cancer Institute (NCI)P3CC (45)
Avelumab
Prostate Cancer
National Cancer Institute (NCI)P2CC (45)
Avelumab
Thymic Carcinoma
National Cancer Institute (NCI)P2CC (45)
Cediranib
Pancreatic Ductal Adenocarcinoma
National Cancer Institute (NCI)P2CC (45)
Defactinib
Melanoma
National Cancer Institute (NCI)P2CC (45)
Dentalfluoro
Renal Cell Carcinoma
National Cancer Institute (NCI)P2CC (45)
Fexagratinib
Melanoma
National Cancer Institute (NCI)P2CC (45)
Fludeoxyglucose
Pancreatic Ductal Adenocarcinoma
National Cancer Institute (NCI)P2CC (45)
Showing 2551 to 2575 of 3,272 assets
PreviousPage 103 of 131Next